Weiwei Yao

Weiwei Yao

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Science of The Total Environment
Verified
Journal Article
Closed access
YYYang Yang
Yang Yang
YWYihang Wang
Yihang Wang
NCNan Cong
Nan Cong
NWNan Wang
Nan Wang
WYWeiwei Yao
Weiwei Yao

1 January 2017 in Journal of Freshwater Ecology
Verified
Journal Article
Open access
WYWeiwei Yao
Weiwei Yao
YCYuansheng Chen
Yuansheng Chen
YZYu Zhong
Yu Zhong
WZWenyi Zhang
Wenyi Zhang
HFHaiyan Fan
Haiyan Fan
In this paper, we describe a model system comprised of hydrodynamic, sediment transport, heat transfer and habitat models. We used this model system to assess the ecosystem situation and investigate the impacts of two ecological restoration strategies in the Mian River, China. Freshwater Reeves shad (Tenualosa reevesii) was selected as the target fish species. Model results indicate a low habitat suitability level for T. reevesii under current hydrological conditions. Due to the habitat protection and restoration requirements in China, further numerical model simulations were conducted to investigate the effects of two ecological restoration strategies: addition of a side-channel and riverbank reconstruction (groin field installation). The long-term effects of the restoration projects were also simulated. The analysis indicated that both restoration strategies would significantly enhance the target fish habitat suitability level, with the OSI (overall suitability index) increasing from 39.9% to 53.7% for the added side-channel strategy and from 39.9% to 61.5% for the river bank reconstruction strategy.

7 March 2023 in Acta Biomaterialia
Verified
Journal Article
Open access
BLBo LI
Bo LI
TYTong Yang
Tong Yang
JLJin Liu
Jin Liu
XYXixi Yu
Xixi Yu
XLXinying Li
Xinying Li
LCLiang Chen
Liang Chen
Non-small cell lung cancer (NSCLC) remains the most frequently diagnosed lung cancer and the leading cause of cancer-related mortality worldwide. PD-1/PD-L1 axis inhibitors have changed the treatment paradigm for various cancer types, including NSCLC. However, success of these inhibitors in lung cancer clinic is severely limited by their inability to inhibit the PD-1/PD-L1 signaling axis due to heavy glycosylation and heterogeneity expression of PD-L1 in NSCLC tumor tissue. Taking advantage of the facts that tumor cell derived nanovesicles could efficiently accumulate in the homotypic tumor sites due to their innate targeting abilities and that specific and high affinity existed between PD-1 and PD-L1, we developed NSCLC targeting biomimetic nanovesicles (NV) cargos from genetically engineered NSCLC cell lines that overexpressed PD-1 (P-NV). We showed that P-NVs efficiently bound NSCLC cells in vitro and targeted tumor nodules in vivo. We further loaded P-NVs with 2-deoxy-D-glucose (2-DG) and doxorubicin (DOX), and found that these drugs co-loaded P-NVs efficiently shrank lung cancers in mouse models for both allograft and autochthonous tumor. Mechanistically, drug-loaded P-NVs efficiently caused cytotoxicity to tumor cells and simultaneously activated anti-tumor immunity function of tumor-infiltrating T cells. Our data therefore strongly argue that 2-DG and DOX co-loaded, PD-1-displaying nanovesicles is a highly promising therapy for treatment of NSCLC in clinic. STATEMENT OF SIGNIFICANCE: Lung cancer cells overexpressing PD-1 are developed for preparing nanoparticles (P-NV). PD-1s displayed on NVs enhance their homologous targeting abilities to tumor cells expressing PD-L1s. Chemotherapeutics such as DOX and 2-DG, are packaged in such nanovesicles (PDG-NV). These nanovesicles efficiently delivered chemotherapeutics to tumor nodules specifically. The synergy between DOX and 2-DG is observed in inhibiting lung cancer cells in vitro and in vivo. Importantly, 2-DG causes deglycosylation and downregulation of PD-L1 on tumor cells while PD-1 displayed on nanovesicles' membrane blocks PD-L1 on tumor cells. 2-DG loaded nanoparticles thus activate anti-tumor activities of T cells in the tumor microenvironment. Our work thus highlights the promising antitumor activity of PDG-NVs, which warrants further clinical evaluation.

1 May 2020 in Tetrahedron
Verified
Journal Article
Closed access
WWWeifan Wang
Weifan Wang
KLKai Lu
Kai Lu
YQYi Qin
Yi Qin
WYWeiwei Yao
Weiwei Yao
DYDandan Yuan
Dandan Yuan
MMMengtao Ma
Mengtao Ma


30 May 2019 in Irrigation and Drainage
Verified
Journal Article
Closed access
PDF file
WYWeiwei Yao
Weiwei Yao
XMXiaoyi Ma
Xiaoyi Ma
YCYuansheng Chen
Yuansheng Chen